LOXL1 Antibody

中文名稱：

LOXL1兔多克隆抗體
貨號：

CSB-PA013040LA01HU
規格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human colon cancer using CSB-PA013040LA01HU at dilution of 1:20
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) LOXL1 Polyclonal antibody
Uniprot No.：

Q08397
基因名：

LOXL1
別名：

LOXL1 antibody; LOXLLysyl oxidase homolog 1 antibody; EC 1.4.3.- antibody; Lysyl oxidase-like protein 1 antibody; LOL antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Lysyl oxidase homolog 1 protein (106-574AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，LOXL1 Antibody (CSB-PA013040LA01HU)，的標記方式是Non-conjugated。對于LOXL1 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA013040LB01HU	LOXL1 Antibody, HRP conjugated	ELISA
FITC	CSB-PA013040LC01HU	LOXL1 Antibody, FITC conjugated
Biotin	CSB-PA013040LD01HU	LOXL1 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:10-1:100

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Active on elastin and collagen substrates.
基因功能參考文獻：
1. the rs11638944:C>G transversion exerts a cis-acting effect on the expression levels of LOXL1, mediated by differential binding of the transcription factor retinoid X receptor alpha and by modulating alternative splicing of LOXL1, eventually leading to reduced levels of LOXL1 mRNA in cells and tissues of risk allele carriers for pseudoexfoliation syndrome PMID: 28534485
2. LOXL1/LOXL2 gene expression and protein levels were increased in Idiopathic pulmonary fibrosis (IPF) versus non-IPF. PMID: 29125826
3. These findings provide evidence for a functional role of alternative splicing coupled to NMD in the posttranscriptional regulation of LOXL1 gene expression and suggest this mechanism to represent a dynamic mode of adapting LOXL1 expression to PEX-associated environmental and nutritional cues. PMID: 29164236
4. remenopausal and postmenopausal women with Pelvic Organ Prolapse (POP) exhibit differential expression of LOXL1 suggesting different pathways in the pathogenesis of POP. The role of biopsy location on LOXL1 expression requires further investigation. PMID: 26829347
5. In this study, we found no significant association between allele and genotype frequencies of APOE; the intronic SNP rs2165241 and the non-synonymous SNP rs3825942 in exon 1 of LOXL1 are significantly associated with pseudoexfoliation syndrome and exfoliation glaucoma in the Turkish population. PMID: 27028259
6. A rare protective allele at LOXL1,Tyr407Phe, was identified. It is found exclusively in the Japanese population. It confers 25-fold resistance to XFS. It segregated with the common rs3825942[A] (p.Asp153) in all but 2 patients examined. In spheroids, this haplotype conferred a significant increase in the strength of cellular adhesion in comparison to 3 haplotypes with the wild-type allele. PMID: 28553957
7. Findings of this current study indicate a different LOXL1 gene expression pattern compared with a recent study that was also performed in the Turkish population. PMID: 27753755
8. LOXL1 transcriptional activity was dramatically reduced when a recombinant DNMT3A was concomitantly overexpressed. PMID: 27396912
9. The present study, for the first time, shows that the pseudoexfoliation syndrome-associated variant residues in LOXL1 influence processing of the protein, most likely by BMP-1. PMID: 26997634
10. In this study group of Turkish population, no LOXL1 mutations were found. No associations between the defined SNPs (A320A, R141L and F184F) and the severity of the disease were detected. PMID: 26758070
11. To identify additional candidate functional variants, we sequenced the entire LOXL1 genomic locus ( approximately 40 kb) in 50 indigenous, black South African XFS cases and 50 matched controls. PMID: 26307087
12. This is the first study associating two SNPs of LOXL1 (rs3825942 and rs2165241) and XFS/XFG in a Spanish population, confirming findings in patients from Europe. PMID: 24892565
13. Our meta-analysis indicates that rs1048661 had weak association with XFG/XFS; rs3825942 had strongly association with XFG/XFS; and rs2165241 had significant risk with XFG/XFS in some ethnicity. PMID: 25304275
14. CTR1, ATP7A, and lysyl oxidase were upregulated in the lung tissues and pulmonary arteries of mice with hypoxia-induced pulmonary hypertension and pulmonary arterial smooth muscle cells. PMID: 24614111
15. Different SNPs in LOXL1 affect risk of pseudoexfoliative glaucoma in different ethnic groups [meta-analysis] PMID: 26404116
16. When the LOXL1 variants were used as disease markers for clinically undetectable exfoliation syndrome (EX), there was no association between central retinal vein occlusion and EX. PMID: 25130441
17. results indicate that hypermethylation of CpG islands in the promoter region of the LOXL1 gene leads directly to downregulation of LOXL1 mRNA and protein, which functions as an essential mechanism in the pathogenesis of Pseudoexfoliation Syndrome PMID: 26348632
18. Data indicate that single-nucleotide polymorphisms (SNPs) distributing in not only lysyl oxidase-like 1 gene (LOXL1) but also TBC1 domain family member 21 protein (TBC1D21) and promyelocytic leukemia protein (PML). PMID: 24938310
19. Single nucleotide polymorphisms of the LOXL1 gene are associated with pseudoexfoliation glaucoma in the Spanish population. PMID: 26319397
20. The polymorphisms of the LOXL1 gene were associated with the susceptibility to primary open-angle glaucoma. PMID: 25750511
21. Our results demonstrate that only a small proportion of individuals with the high-risk GG/GG diplotype may actually be found to clinically manifest exfoliation syndrome. PMID: 25041436
22. Data suggest that expression of LOXL1 and FBLN5 (fibulin 5) (but not expression of elastin) is down-regulated in uterosacral ligaments of postmenopausal women with pelvic organ prolapse. PMID: 22487196
23. This polymorphism seems to be associated with high risk for primary open-angle glaucoma in a Mediterranean population. PMID: 24893574
24. p66beta might be important for the regulation of LOX in the nucleus. PMID: 25118846
25. There were no significant difference in allele frequency distribution of LOXL1 rs1048661rs3825942 and rs2165241 between primary open-angle glaucoma (POAG) and normal controls (P=0.322, P=0.660, P=0.965). PMID: 25636109
26. Pathogenetic stimuli induced a significant increase in the expression of LOXL1 and elastic proteins and resulted in their assembly into exfoliation syndrome-like fibrils in vitro. PMID: 25275906
27. Collectively, these results suggest that dysregulation of LOXL1 expression is a contributing factor to exfoliation disease development. PMID: 25275910
28. Human LOX gene encodes 2 variants, LOX and LOX-v2, both of which function as amine oxidases with distinct tissue specificities. PMID: 25017124
29. Studies suggest that LOXL1 rs1048661 TT, rs3825942 AA, and rs2165241 CC were associated with a reduced risk of developing pseudoexfoliation syndrome and pseudoexfoliation glaucoma (PEXS/PEXG). PMID: 24603551
30. Haplotypes of LOXL1 are associated with PG-PDS independently from rs1048661, leading to a differential expression of the transcript. PMID: 24739284
31. Sequencing of 7 exons and regulatory regions of LOXL1 identified 11 additional sequence variants; only rs41435250 showed an association (P = 3.80 x 10-5 [0.49]) with pseudoexfoliation syndrome and glaucoma PMID: 24809751
32. LOXL1 gene contributes to onset of PEXG through PEX. Gene variants of LOXL1 do not help to identify those with PEX at increased risk for glaucoma development. PMID: 24917141
33. allele T of LOXL1 rs41435250 is a novel risk genetic factor for pseudoexfoliation syndrome/pseudoexfoliation glaucoma development. PMID: 24068861
34. High Lysyl Oxidase expression is associated with non-small cell lung cancer. PMID: 23886154
35. LOXL1 is more abundant in the deposits in the iris region and, alternatively APOE is concentrated in the PEX material accumulated in the pupillary area of the anterior lens capsule. PMID: 23411028
36. The homozygote TT polymorphism in the rs1048661 and rs2165241 region of LOX-L1 gene may be responsible for stress urinary incontinance physiopathology. PMID: 22765198
37. Association of LOXL1 with exfoliation syndrome and exfoliation glaucoma was investigated and apolipoprotein E and MTHFR polymorphisms as genetic risk factors for both conditions, were evaluated. PMID: 23687437
38. Certain genetic variants in LOXL1 confer risk for pseudoexfoliation syndrome in Greek populations. PMID: 23869164
39. Three SNPs of LOXL1 (rs1048661, rs3825942, and 2,165,241) are highly associated with pseudoexfoliation syndrome in a Korean population. PMID: 23441117
40. None of the patients with exfoliation syndrome/glaucoma has the adenine (A) allele single nucleotide polymorphism (SNP) of rs3825942, whereas 16% of the control subjects have the LOXL1 variant. PMID: 23378724
41. Knockdown of E2F1 stabilized HIF-1alpha and promoted LOX expression, while knockdown of both E2F1 and HIF-1alpha prevented the up-regulation of LOX PMID: 23196386
42. There was no significant difference in the frequency of the DNA copy number variants in the LOXL1 region between the exfoliation glaucoma cases and the controls. PMID: 23288989
43. The -22G/C polymorphism may affect the expression of LOX, and that -22G/C and 473G/A polymorphisms may be new risk factors for osteosarcoma. PMID: 22911823
44. study suggests that LOX G473A polymorphism is a new risk factor for ovarian cancer and that LOX protein might be a possible therapeutic target in ovarian cancer PMID: 22906264
45. A significant association was found for the G allele of rs1048661 and rs3825942 in pseudoexfoliative glaucoma patients of Pakistani origin. PMID: 22605916
46. The findings provide evidence for a pseudoexfoliation-specific elastinopathy of the lamina cribrosa resulting from a primary disturbance in LOXL1 regulation and elastic fiber homeostasis. PMID: 22633114
47. The Saudi Arabian primary open angle glaucoma (POAG) population, similar to all other populations studied to date, demonstrates no association with SNPs associated with pseudoexfoliation glaucoma. PMID: 21510775
48. The R141L and G153D variations in the NH2-terminal region of LOXL1 do not affect the amine oxidase activity of LOXL1 associated with exfoliation glaucoma. PMID: 22328822
49. Spectroscopic results show that in all cases lysyl oxidase folds correctly but that the copper content, enzymatic activity, and redox-cycling ability depends on the mutation. PMID: 21190048
50. Transforming Growth Factor-Beta induces up-regulation expression of lysyl oxidase family in anterior cruciate ligament and medial collateral ligament fibroblasts. PMID: 21674292
顯示更多

收起更多
相關疾病：

Exfoliation syndrome (XFS)
亞細胞定位：

Secreted, extracellular space.
蛋白家族：

Lysyl oxidase family
組織特異性：

Expressed in ocular tissues including the iris, ciliary body, lens and optic nerve. Not detected in the retina.
數據庫鏈接：

HGNC: 6665

OMIM: 153456

KEGG: hsa:4016

STRING: 9606.ENSP00000261921

UniGene: Hs.65436

Most popular with customers

YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human